CDSCO Group Approves CT Phase IV of Commercial Use of Hetero-Trastuzumab

Published Date: 20 Mar 2023

NEW DELHI: Hetero Biopharma, a pharmaceutical major, has received Securities and Exchange Commission (SEC) approval to operate under the Central Pharmaceutical Standards...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot